title: Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
abstract: OBJECTIVE
  Clinafloxacin is a novel quinolone with wide activity against the plethora of microorganisms encountered in intraabdominal infections. This trial was performed to examine its clinical efficacy.
  
  
  BACKGROUND
  Clinafloxacin is representative of a new class of quinolones with considerable antimicrobial activity resulting from their mechanisms of action and pharmacodynamics. There is, however, concern about specific potential toxicities, including photosensitivity.
  
  
  METHODS
  This prospective, randomized, double-blind trial was conducted to compare clinafloxacin with imipenem/cilastatin as adjuncts in the management of complicated intraabdominal infections.
  
  
  RESULTS
  Five hundred twenty-nine patients were included in the intent-to-treat population, with 312 meeting all criteria for the valid population. Patients with a wide range of infections were enrolled; perforated or abscessed appendicitis was the most common (approximately 50%). One hundred twenty-three of the 150 valid patients treated with clinafloxacin (82%) had successful outcomes, as did 130 of the 162 (80%) treated with imipenem. For the intent-to-treat groups, 219 of 259 patients treated with clinafloxacin (85%) had successful outcomes, as did 219 of 270 patients treated with imipenem/cilastatin (81%). Treatment failure occurred in 39 patients who underwent drainage. There were substantially more gram-negative organisms recovered from the patients with treatment failure who were initially treated with imipenem/cilastatin.
  
  
  CONCLUSIONS
  The results of this study clearly demonstrate the safety and efficacy of clinafloxacin in the treatment of a range of intraabdominal infections, and in patients with a broad range of physiologic disturbances.
authors.affiliation: Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0558, USA. joseph.solomkin@uc.edu
authors.forename: J S
authors.initials: JS
authors.lastname: Solomkin
authors.forename: S E
authors.initials: SE
authors.lastname: Wilson
authors.forename: N V
authors.initials: NV
authors.lastname: Christou
authors.forename: O D
authors.initials: OD
authors.lastname: Rotstein
authors.forename: E P
authors.initials: EP
authors.lastname: Dellinger
authors.forename: R S
authors.initials: RS
authors.lastname: Bennion
authors.forename: R
authors.initials: R
authors.lastname: Pak
authors.forename: K
authors.initials: K
authors.lastname: Tack
mesh_terms: D000005:Abdomen; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000627:therapeutic use*; D013845:Thienamycins / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; C057477:clinafloxacin